MRNA, VRA Lead EPS Revision Screener Winners With 20.9%, 15.4% Gains
Moderna surged 20.9% to $238.12 after our EPS revision screener detected it on October 8 at $197.00, with next-year EPS growth now at 42.9%. Vera Bradley jumped 15.4% to $5.93 following a massive 63.6 percentage-point upward revision to its next-year EPS growth estimate (86.4% to 150.0%), while Repligen added 12.8% to $184.77 ahead of its October 27 earnings report.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| MRNA | Healthcare | 2026-10-08 | N/A | +20.9% |
| VRA | Consumer Cyclical | 2026-10-09 | +63.6pp | +15.4% |
| RGEN | Healthcare | 2026-10-08 | N/A | +12.8% |
| AGBK | Financial | 2026-10-08 | N/A | +11.2% |
| WQEY | Technology | 2026-10-09 | +12.4pp | +8.9% |
Why did MRNA stock jump in October 2026?
MRNA jumped 20.9% (from $197.00 to $238.12) after analysts raised its next-year EPS growth estimate to 42.9% on October 8.
The revision signaled improving profitability expectations for the biotech, which will report Q3 2026 results on November 6. Moderna has been navigating a post-pandemic transition, and the upward estimate suggests the market is pricing in stronger cost controls and pipeline progress. The stock's rally accelerated as broader healthcare sector rotation favored beaten-down biotech names with visible earnings inflection.
MRNA EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: MRNA
Why did MRNA stock jump in October 2026?
MRNA jumped 20.9% from $197.00 to $238.12 after its next-year EPS growth estimate was revised upward to 42.9% on October 8, 2026.
Is MRNA a buy after the rally?
Analysts now project 42.9% next-year EPS growth, but the stock's 20.9% gain in one week may have already priced in near-term optimism ahead of its November 6 Q3 report.
What caused Moderna's surge?
The surge was triggered by an EPS estimate revision detected on October 8, with next-year growth set at 42.9%, reinforcing confidence ahead of Q3 earnings on November 6.
Why did VRA stock jump in October 2026?
VRA jumped 15.4% (from $5.14 to $5.93) after its next-year EPS growth estimate was revised from 86.4% to 150.0% on October 9.
The 63.6 percentage-point upward revision is one of the largest in our screener, signaling a dramatic turnaround in profitability expectations for the consumer accessories brand. With no company-specific news in the window, the move likely reflects broader optimism around retail inventory normalization and margin recovery. The magnitude of the estimate shift suggests analysts see substantial operating leverage ahead.
VRA EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: VRA
Why did VRA stock jump in October 2026?
VRA jumped 15.4% from $5.14 to $5.93 after its next-year EPS growth estimate was revised from 86.4% to 150.0% on October 9, 2026.
What is VRA's EPS growth estimate?
Vera Bradley's next-year EPS growth estimate now stands at 150.0%, up from 86.4% previously, a 63.6 percentage-point revision.
Is Vera Bradley a buy after the rally?
The 150.0% next-year EPS growth estimate is bullish, but the 15.4% price gain since detection may already reflect much of the near-term upside without confirmed earnings results.
Why did RGEN stock jump in October 2026?
RGEN jumped 12.8% (from $163.84 to $184.77) after analysts raised its next-year EPS growth estimate to 27.9% on October 8.
The bioprocessing company announced on October 13 it will report Q3 2026 results on October 27, giving investors a near-term catalyst to validate the improved earnings outlook. Repligen's filtration and chromatography systems are seeing renewed demand as biopharma manufacturing activity stabilizes. The screener flagged the revision early, and the market confirmed it with steady buying into the earnings date.
RGEN EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: RGEN
Why did RGEN stock jump in October 2026?
RGEN jumped 12.8% from $163.84 to $184.77 after its next-year EPS growth estimate was revised to 27.9% on October 8, 2026.
When does Repligen report Q3 2026 earnings?
Repligen will report Q3 2026 financial results on October 27, 2026, before market open, with a conference call at 8:00 a.m. ET.
Is RGEN a buy after the rally?
With a 27.9% next-year EPS growth estimate and Q3 earnings on October 27, the stock has momentum, but the 12.8% gain may limit near-term upside unless results beat expectations.
Why did AGBK stock jump in October 2026?
AGBK jumped 11.2% (from $6.51 to $7.24) after its next-year EPS growth estimate was revised to 44.5% on October 8.
The financial sector stock benefited from the revision despite no company-specific news, suggesting the move was driven by broader sector rotation into higher-growth financial names. Rising Treasury yields, with the 10-year near 5.24%, have improved net interest margin outlooks for banks and financial services firms. The screener caught the estimate increase early, and the market followed through with steady accumulation.
AGBK EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: AGBK
Why did AGBK stock jump in October 2026?
AGBK jumped 11.2% from $6.51 to $7.24 after its next-year EPS growth estimate was revised to 44.5% on October 8, 2026.
What caused AGBK's surge?
The surge was driven by a 44.5% next-year EPS growth estimate revision and broader financial sector strength as the 10-year Treasury yield hovered near 5.24%.
Is AGBK a buy after the rally?
The 44.5% next-year EPS growth estimate supports a bullish case, but with no company-specific news, the 11.2% gain may be largely sector-driven and vulnerable to interest rate shifts.
Why did WQEY stock jump in October 2026?
WQEY jumped 8.9% (from $8.61 to $9.38) after analysts raised its next-year EPS growth estimate from 34.0% to 46.3% on October 9.
The 12.4 percentage-point upward revision reflects improving profit expectations for the technology company, though no specific news catalyst was identified in the window. The gain aligns with broader tech sector resilience, even as chip stocks faced pressure from Chinese competition. The screener detected the revision early, and the market's steady buying suggests confidence in the upgraded earnings trajectory.
WQEY EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: WQEY
Why did WQEY stock jump in October 2026?
WQEY jumped 8.9% from $8.61 to $9.38 after its next-year EPS growth estimate was revised from 34.0% to 46.3% on October 9, 2026.
What is WQEY's EPS growth estimate?
WISeQey Corp's next-year EPS growth estimate is now 46.3%, up from 34.0%, a 12.4 percentage-point increase.
Is WQEY a buy after the rally?
The 46.3% next-year EPS growth estimate is a positive signal, but the 8.9% gain since detection may already reflect the revision, and no company-specific catalyst has been identified.
Today's top performers highlight that EPS estimate revisions remain a powerful catalyst, particularly in healthcare and consumer cyclical names where profitability inflections are being repriced. Moderna's 20.9% gain and Vera Bradley's massive 63.6 percentage-point revision suggest the market is rewarding companies with visible earnings acceleration, even without immediate news catalysts.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →